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Adding a long-acting b2-agonist to inhaled corticosteroids (ICS) for asthma treatment is better
than increasing ICS dose in improving clinical status, although there is no consensus about the
impact of this regimen on inflammation. In this double-blind, randomized, parallel group
study, asthmatics with moderate to severe disease used budesonide (400 mcg/day) for 5 weeks
(run-in period); then they were randomized to use budesonide (800 mcg/day e BUD group) or
budesonide plus formoterol (400 mcg and 24 mcg/day, respectively e FORMO group) for 9
weeks (treatment period). Home PEF measurements, symptom daily reporting, spirometry,
sputum induction (for differential cell counts and sputum cell cultures), and hypertonic saline
bronchial challenge test were performed before and after treatments. TNF-a, IL-4 and eotax-
in-2 levels in the sputum and cell culture supernatants were determined. Morning and night
PEF values increased in the FORMO group during the treatment period (p < 0.01), from
435 162 to 489 169 and 428 160 to 496 173 L/min, respectively. The rate of exacerba-
tions in the FORMO group was lower than in the BUD group (p< 0.05). Neutrophil counts in spu-
tum increased in both groups (p< 0.05) and leukocyte viability after 48 h-culture increased in
the FORMO group (p< 0.05). No other parameter changed significantly in either group. This
study showed that adding formoterol to budesonide improved home PEF and provided protec-
tion from exacerbations, although increase of leukocyte viability in cell culture may be a mat-
ter of concern and needs further investigation.
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1386 M.B. Menezes et al.Introduction the open-label run-in period, all patients received inhaledAsthma is a chronic inflammatory airway disorder charac-
terized by reversible airflow obstruction and bronchial
hyperresponsiveness to a variety of stimuli; several types
of cells and mediators are involved in its pathophysiology.
The mainstay of persistent asthma management is the
regular use of inhaled corticosteroids (ICSs)1; they modu-
late many inflammatory processes by reducing the number
of inflammatory cells in the airways of asthmatic subjects
and by inhibiting the release of inflammatory mediators,
contributing to the achievement of clinical control.2
Nonetheless, there is concern about possible systemic
side effects of these drugs, so it is advised that the minimum
dose needed to control symptoms should be used. Other
largely used controller drugs are the long-acting b2-agonists
(LABAs), which are considered to be smooth muscle relax-
ants, while their action upon inflammation is still a matter
of debate. Although LABAs must not be used as monotherapy
in asthma treatment, it has been shown that subjects still
symptomatic while taking only ICSs achieve greater clinical
control and better lung function with addition of LABA rather
than with increasing the dose of ICS.3e6 Moreover, the
association of these drugs exposes the patients to less risk
of ICS systemic side effects. In addition, some authors have
shown (both in vitro and in vivo) that the association of the
drugs may have beneficial effects even on inflammatory
parameters.7e10
The safety of LABAs has been questioned since their
introduction as controller therapy, and a recent multicen-
ter study showed greater mortality in the group of patients
who used this class of drug, strengthening the contro-
versy.11 Furthermore, some studies have shown that LABAs
may have a pro-inflammatory effect, and their addition to
ICSs may mask ongoing inflammation while offering
satisfactory symptomatic relief.12e14
The aim of the present study was to observe clinical and
inflammatory outcomes of two 9-week treatment regimens:
budesonide, 800 mg daily and budesonide, 400 mg daily plus
formoterol, 24 mg daily in patients who were previously
taking budesonide 400 mg daily.
Materials and methods
Subjects
Male and female asthmatic patients aged 18e60 years were
recruited from the asthma clinic of the University Hospital
(University of Sa˜o Paulo, Ribeira˜o Preto, Brazil). All of them
were considered to suffer from asthma with positive bron-
chial challenge test and forced expiratory volume in 1 s
(FEV1) 60% of the predicted value at baseline evaluation.
Exclusion criteria included current smoking or a history of
more than 10 pack-years smoking, respiratory disorders
other than asthma, exacerbation, airway infections and/or
use of systemic corticosteroids during the previous 4 weeks.
Study design
This was a double-blind, randomized, parallel group study
consisting of a run-in period and a treatment period. Duringbudesonide 200-mg bid as control medication for 5 weeks
and were then randomized to a 9-week treatment with
twice daily inhalations of either budesonide 400 mg (BUD
group) or budesonide 200 mg plus formoterol 12 mcg
(FORMO group).
Budesonide was administered in 200 mg doses, thus BUD
group was treated with two 200 mg-doses bid (i.e., 800 mg/
day) and FORMO group also received two doses (one 200 mg
budesonide dose and one 12 mg formoterol dose) bid. Dry
powder inhaler (aerolizer) system was used for both
budesonide and formoterol. Inhaled albuterol was used as
the only reliever drug throughout the study. Treatment with
other anti-asthma drugs was not allowed.
All patients were evaluated in a first visit (visit 1), in
which the investigators assessed the fulfillment of inclusion
criteria, provided the run-in period medication, symptom
diary cards and peak expiratory flow (PEF) meters. Patients
were instructed to perform PEF measurements and symp-
tom diary recordings daily during weeks 3 and 4. By the end
of week 4, the patients were evaluated in visit 2, in which
they underwent spirometry and induction of sputum. During
week 5, they used the same run-in medication and by the
end of that week they underwent a hypertonic saline (HS)
challenge test and were randomized to one of the treat-
ment groups in visit 3. By the end of week 9, in visit 4, they
underwent spirometry, received symptom diary cards, and
were instructed to record symptoms and PEF measurements
daily through weeks 12 and 13. By the end of week 13,
another spirometry and sputum induction were performed
in visit 5; all patients kept using the same treatment during
week 14, by the end of which a HS challenge test was
performed, in visit 6. The randomized code was withheld
from the investigators until the completion of the study.
The study was approved by the Ethics Committee of the
University of Sa˜o Paulo Medical School at Ribeira˜o Preto,
and all subjects gave written informed consent.
Peak expiratory flow measurements and
symptom diary cards recordings
The patients were carefully instructed about the use of the
Mini-Wright PEF meters (Clement Clarke, Essex, UK). The
measurements were performed prior to the inhalation of
any medication, and the highest value of three consecutive
measurements was recorded both in the morning and at
night. The variability of PEF measurements was calculated
using the formula:
DPEFZ
night PEFmorning PEF
night PEF
 100
Patients also recorded symptoms of asthma on symptom
diary cards.
Spirometry
All spirometry measurements were performed by the same
investigator, in the morning, using a Koko pneumotacho-
graph and software (PDS Instrumentation, Inc., Louisville,
Colorado, USA). Post-bronchodilator measurements were
performed 15 min after the inhalation of 200 mg of
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medications during the 12 h that preceded the procedure.
Sputum induction and processing
The guidelines of the Task Force on Induced Sputum of the
European Respiratory Society15 were applied. All patients
had an FEV1 60% immediately before the procedure. After
pre-medication with 200 mg of inhaled albuterol and gargling
of nistatin (to minimize fungus contamination), sputum
induction was performed by inhalation of a hypertonic saline
(4.5% NaCl) aerosol delivered by an ultrasonic nebulizer
(Ultra-Neb 2000; DeVilbiss, Somerset, PA, USA). The inhala-
tion duration was 20 min, divided into four 5-min periods.
For safety reasons, a PEFmeasurement was performed every
5 min and the procedure was stopped if the PEF fell to the
critical value (a 10% fall from the basal value) or if there
were bothersome symptoms. If a subject tolerated less
than 20 min of induction in visit 3, then the duration of
induction in visit 6 would be the same as in visit 3. During
the induction, the subjects were encouraged to spit saliva
into a plastic container and sputum into another pre-
weighed sterile one anytime they wished. The saliva was
discarded and the sputum was weighed; 1 mL of 0.1% dithio-
threithol (DTT; GIBCO BRL, Grand Island, NY, USA) per gram
of sputum was added and the suspension was shaken in
a vortex mixer for a few seconds and incubated in a shaking
water bath (Dubnoff TE-053; TECNAL, Piracicaba, SP, Brazil)
at 37 C (150 cycles/min) for 15 min, with periodic brief
aspirations. The sample was centrifuged at 750g for
10 min (Allegra 21R Centrifuge; Beckman, Palo Alto, CA,
USA) and the supernatant was aspirated and stored at
85 C. The cell pellet was re-suspended in 1 mL of culture
medium containing 300 mg/L L-glutamine, 100 U/mL penicil-
lin G, 100 mg/mL streptomycin sulphate (RPMI-1640; GIBCO
BRL, Grand Island, NY, USA) and 10% calf serum. Total cell
number and cell viability were determined by the Trypan
blue exclusionmethod in a Neubauer chamber (FeineOptik,
Blackenburg, Germany) and slides were prepared for differ-
ential cell counts by cytospin staining with Giemsa and May-
Grumwald stains. The cell concentration was adjusted to
1 106 viable cells per milliliter of culture medium.
Cell culture
The cell suspension was plated at 5 105 cells/well onto
a 48-well plastic culture plate (Nunc Brand Products,
Roskilde, Denmark) and allowed to adhere for 1 h at 37 C
in 5% CO2 humidified environment (NuAire IR autoflow;
NuAire, Plymouth, MN, USA). After this period, the superna-
tant of every well was aspirated to remove non-adherent
cells and the wells were washed twice with phosphate buff-
ered saline (PBS) at 37 C. The cells that were not removed
were named adherent cells; they were kept in the same
wells and 0.5 mL/well of culture medium and 0.01 mL/well
of lipopolysaccharide (LPS; GIBCO BRL, Grand Island, NY,
USA) were added (some wells were left without addition of
LPS, and were named non-stimulated adherent cells).
The number and viability of the non-adherent cell
population were determined as described above. These cells
were re-plated at 1 105 viable cells/well with medium(0.2 mL/well) in 96-well plastic culture plates (Nunc Brand
Products) and with 0.01 mL/well of phytohaemagglutinin
(PHA; GIBCO BRL, Grand Island, NY, USA); some wells were
left without addition of PHA, andwere named non-stimulated
non-adherent cells. The adherent and non-adherent cells
were incubated for 48 h at 37 C in 5% CO2 humidified
environment. After the completion of culture period, the
cells were removed from the plates and the samples were
centrifuged; the supernatants were removed and stored at
85 C until the dosages of mediators were performed.
Hypertonic saline challenge test
The HS challenge tests were carried out according to the
protocol developed by Anderson and Brannan.16 The
ultrasonic nebulizer (De Vilbiss Ultra-neb 2000; De Vilbiss,
Somerset, PA, USA) was connected to a two-way non-
rebreathing valve (Hans Rudolph 2700 series; Kansas City,
MO, USA) via 100 cm of corrugated aerosol tubing (internal
diameterZ 2,2 cm, smooth internal surface) with a rubber
mouthpiece and a nose clip. The nebulizer canister was filled
with 200 mL of 4,5% NaCl, and the output was set to
maximum. Previous studies have shown that the output of
this nebulizer system, at tidal volumes of 300e500 mL and
respiratory rates of 12e20/min, ranges from 1.9 to 2.5 mL/
min, with a particle size distribution of mass median aerody-
namic diameter between 2.33 and 2.87 mm.17 After three
reproducible measurements of baseline FEV1, subjects
breathed through the valve with the nebulizer switched off
for 2 min and then started breathing the HS aerosol with an
initial exposure period of 30 s. After this first inhalation of
30 s, subjects breathed increasing doses of HS by doubling
the duration of nebulization (1, 2, 4, and 8 min). FEV1 was
measured in duplicate, 90 s after breathing through the valve
and after each inhalation. If FEV1 fell less than 10% of base-
line, the exposure time was doubled. If the reduction of
FEV1 was more than 10% and less than 20%, the exposure
timewas repeated rather than doubled. The test was stopped
when a fall of 20% or more was obtained or with a total expo-
sure time of 15.5 min. Then, 200 mg albuterol was adminis-
tered. The nebulizing canister and tubing were weighed
before the challenge and after the final inhalation step using
an electronic balance (AS 2000; Marte, Sa˜o Paulo, SP, Brazil)
to assess the total amount of aerosol nebulized and the
nebulizer output. Patients were questioned about the inten-
sity of dyspnea at every inhalation. The tests were performed
with a Koko pneumotachograph and software. All patients
were asked towithhold all inhaled drugs 12 h before the tests.
Measurement of inflammatory mediators
The concentrations of interleukin-4 (IL-4), tumor necrosis
factor-a (TNF-a) and eotaxin-2 in sputum fluid and cell
culture medium were determined by ELISA (R&D systems,
Minneapolis, MN and Pharmingen, San Diego, CA, USA).
Statistical analysis
Data are expressed as mean  standard deviation, unless
otherwise specified. Intra-group comparisons between run-
in and treatment periods were performed by Wilcoxon
Table 1 Characteristics of the subjects
BUD group FORMO group p
Age, yr 43.0 (10.6) 40.1 (14.0) 0.50
Sex (male/female), n 4/6 6/4 0.65
FEV1 (%) 81.2 (9.3) 85.9 (9.2) 0.16
Morning PEF (%) 83.6 (5.6) 93.4 (22.0) 0.37
Night PEF (%) 85.8 (8.7) 91.8 (21.7) 0.86
DPEF (%) 2.2 (6.1) 1.8 (3.8) 0.08
PD20 HS (g) 19.3 (10.7) 13.1 (10.0) 0.23
Symptom-free days (%) 71.4 (40.4) 77.1 (31.5) 0.50
Sputum eosinophils (%) 8.2 (15.7) 11.2 (18.8) 0.36
BD response (%) 10.8 (6.6) 7.3 (7.3) 0.24
All data, except sex, are presented as means (standard
deviation).
FEV1 (%): forced expiratory volume in one second (percentage
of predicted) on visit 2; PEF (%): mean peak expiratory flow
(percentage of predicted) in the 7 days before visit 2; DPEF:
mean daily variation of PEF in the 7 days before visit 2; PD20
HS: hypertonic saline mass that provoked a 20% fall in FEV1
in visit 3; Symptom-free days (%): percentage of days free of
asthma symptoms during the 14 days that preceded visit 2;
Sputum eosinophils (%): percentage of eosinophils in sputum
in visit 2; BD response: FEV1 percent increase after albuterol
use in visit 2.
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proportions between groups. Correlations were calculated
by Pearson correlation. A p value of 0.05 was considered
to be statistically significant.
Results
Thirty-two patients were randomized: 19 to the BUD group
and 13 to the FORMO group. In the BUD group and the
FORMO group, eight and one patients, respectively, were
excluded due to exacerbations, and the rates of exacerba-
tions were significantly different between the groups
(p< 0.05; Fisher exact test). One and two patients aban-
doned the BUD and the FORMO groups, respectively. Twenty
patients completed both the study periods, 10 in each
group. Table 1 shows the characteristics of these 20
patients at the end of the run-in period; there were no
significant differences between the groups.
Clinical, functional and inflammatory parameters
In the BUD group, there were not statistically significant
differences in clinical, functional or inflammatory param-
eters in the comparison of the run-in and the treatment
periods, whereas in the FORMO group, there were increases
in morning and night PEF in the treatment period (Table 2).
The increase in morning PEF during the treatment period
correlated with the bronchodilator response during the
run-in period in the BUD group (rZ 0.78; pZ 0.008) as
well as in the FORMO group (rZ 0.72; pZ 0.018).
Induced sputum
Fig. 1 shows eosinophil counts in the run-in and treatment
periods in both groups; there was no significant difference
between the run-in and the treatment periods in any group.
Table 3 shows the differential cell counts in sputum in the
run-in and treatment periods in both groups; there was an
increase in neutrophil counts in both groups during the
treatment period.
Cell cultures
The percentages of viable cells (vitalities) after culture
were similar in the run-in and treatment periods in both
groups, except for the non-stimulated non-adherent cells in
the FORMO group, in which there was a raise in viability in
the treatment period compared to the run-in period;
run-in: 87.4 (7.2)%; treatment: 93.3 (3.9) %; p< 0.05.
Cytokines concentrations
There were no statistically significant differences between
the periods in any group concerning the concentrations of
TNF-a, IL-4 or eotaxin-2 in sputum supernatants and cell
culture supernatants.
Discussion
In the present study, the addition of either 24 mg of formo-
terol or 400 mg of budesonide per day failed to furthermodify most inflammatory parameters compared to the
use of budesonide 200 mg bid in patients with moderate
and severe asthma, although the association of drugs
improved lung function and reduced exacerbations.
The superiority of the ‘‘add-on’’ therapy in improving
symptoms and functional parameters has been previously
demonstrated,3e6 and addition of a LABA to daily regimen
of ICSs is the recommended step when patients do not
achieve clinical control while taking medium dose of
inhaled corticosteroids, according to recent protocols.1
Some authors believe that the add-on therapy is better
than the rising of ICS doses even when patients are not
clinically stable on low doses of ICSs.18 Our data illustrated
the rising of PEF measurements, but failed to demonstrate
any rise in FEV1 during the use of formoterol plus
budesonide. This may have happened because the use of
formoterol was withheld before spirometry, but not before
PEF measurements; the latter reflects more properly the
actual functional status of asthmatics who take bronchodi-
lators on a regular basis, and that is why some authors have
used PEF as a primary end-point on studies assessing LABA
efficacy.4 Doubling the dose of ICSs did not result in any
improvement of lung function, perhaps because of a flat
dose-response curve of ICSs (as mentioned below).
We showed significant correlation between magnitude of
bronchodilator response in the run-in period and improve-
ment of PEF during the treatment period in both groups. It
seems that individuals using low dose of budesonide whose
response to bronchodilator is greater may have bigger
functional improvement when treatment is stepped-up.
We chose an indirect challenge test (hypertonic saline)
instead of a direct challenge test because indirect stimuli
act on inflammatory cells, not on effector cells, so they
probably reflect more properly the inflammatory status of
the airways.16,19 The decrease of airway responsiveness to
Table 2 Functional and inflammatory responses to treatments
BUD group FORMO group
Run-in Treatment Run-in Treatment
FEV1 (%) 81.2 (9.3) 81.5 (9.1) 85.9 (9.2) 88.1 (11.0)
Morning PEF (% predicted) 83.6 (5.6) 90.4 (12.7) 93.4 (22.0) 105.5 (24.2)*
Night PEF (% predicted) 85.8 (8.7) 91.4 (15.3) 91.8 (21.7) 106.9 (23.6)*
Morning PEF (L/min) 348.0 (72.9) 375.1 (84.9) 435.3 (161.8) 489.3 (169.5)*
Night PEF (L/min) 356.2 (74.7) 380.0 (99.2) 428.3 (159.9) 496.3 (172.9)*
DPEF (%) 2.2 (6.1) 0.6 (6.6) 1.8 (3.8) 1.29 (5.3)
PD20 HS (g) 19.3 (10.7) 20.5 (11.8) 13.1 (10.0) 16.7 (11.1)
Symptom-free days (%) 71.4 (40.4) 1.9 (4.1) 77.1 (31.5) 2.9 (5.2)
Sputum eosinophils (%) 8.2 (15.7) 3.9 (3.4) 11.2 (18.8) 4.3 (2.9)
BD response (%) 10.8 (6.6) 11.8 (9.5) 7.3 (7.3) 3.1 (4.6)
All data are presented as mean (standard deviation).
FEV1 (%): forced expiratory volume in one second (percentage of predicted) on visit 2 (run-in) and on visit 5 (treatment); PEF (%): mean
peak expiratory flow (% predicted) in the 7 days before visit 2 (run-in) and before visit 5 (treatment); D PEF: mean daily variation of PEF
in the 7 days before visit 2 (run-in) and before visit 5 (treatment); PD20 HS: hypertonic saline mass that provoked a 20% fall in FEV1 on
visit 3 (run-in) and on visit 6 (treatment); Symptom-free days (%): percentage of days free of asthma symptoms during the 14 days that
preceded visit 2 (run-in) and visit 5 (treatment); Sputum eosinophils (%): percentage of eosinophils in sputum on visit 2 (run-in) and on
visit 5 (treatment); BD response: FEV1 percent increase after albuterol use on visit 2 (run-in) and on visit 5 (treatment).
*p< 0.01 in the run-in period vs. treatment period.
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previously,19e22 but in our study there was not such an
effect in any group. Perhaps that happened because the
ICS and/or LABA doses were not sufficient to provide
more bronchoprotective effect than the dose of the run-
in period. We do not believe that the length of the treat-
ment period was too short since other authors have shown
that 8 weeks of therapy (or even less) are enough to
achieve an effect on hyperresponsiveness.19e22
The action of LABAs on inflammation of the airways is still
a matter of debate. McIvor et al. have demonstrated that
when the dose of ICSs was gradually reduced, asthmatic
patients taking high doses of ICSs plus salmeterol (a LABA)
suffered from little clinical deterioration despite a marked
rise in sputum eosinophils, indicating that LABAs may
‘‘mask’’ ongoing inflammation.13 Such a masking effect
may be the reason why our FORMO group had fewer exacer-
bations; i.e., perhaps the symptomatic relief prevented
them from noticing a worsening of airway inflammation.
Nevertheless, other authors have shown some anti-
inflammatory properties of LABAs, both in vitro and in
vivo. In one of these studies, patients who were taking
only an ICS as controller medication were randomized to0.1
1
10
100
Run-in Treatment
A B
Eo
sin
op
hi
ls 
(   
 )
Eo
sin
op
hi
ls 
(   
 )
Figure 1 Individual values of eosinophil counts (in percentage of l
and (B) FORMO group. Horizontal lines indicate means, p > 0.3 in b
periods (Wilcoxon).one of three groups, in which they took, in addition to
the dose of ICSs they were already taking, respectively:
salmeterol, fluticasone, or placebo for 12 weeks. Endobron-
chial biopsies before and after the treatment regimens
evidenced that only the ones who took salmeterol had
eosinophilic cationic protein (ECP)-positive eosinophil
counts decrease on the bronchial wall.7 In another study,
asthmatic subjects treated with a fixed dose of ICS under-
went treatment with an equivalent dose of fluticasone
plus salmeterol for 12 weeks; this intervention resulted in
a lowering of mast cells number on the bronchial submu-
cous layer, as assessed by comparison of endobronchial
biopsy specimens before and after the treatment period.10
On the other hand, several studies failed to demonstrate
pro- or anti-inflammatory properties of the association of
drugs, similarly to our data. Some authors conducted
a study in which asthmatic subjects took a high dose of
budesonide daily during a run-in period and were then
randomly assigned to low dose of budesonide plus formo-
terol or medium dose of budesonide. There was no de-
terioration of inflammatory parameters in any of the
groups, so the authors concluded that the association of
drugs does not lead to worsening of inflammatory status.230.1
1
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100
Run-in Treatment
eukocytes) in the Run-in and Treatment periods in (A) BUD group
oth groups for the comparison between Run-in and Treatment
Table 3 Differential cell counts in the run-in and treatment periods
BUD group FORMO group
Run-in Treatment Run-in Treatment
Squamous cells (%) 12.8 (8.5) 12.6 (8.7) 16.0 (13.9) 17.3 (16.8)
Eosinophils (%) 8.2 (15.7) 3.9 (3.4) 11.2 (18.8) 4.3 (2.9)
Neutrophils (%) 29.0 (14.1) 39.2 (11.0)* 23.0 (12.6) 39.3 (18.1)*
Macrophages (%) 55.4 (20.0) 49.1 (13.0) 56.9 (19.2) 44.9 (18.2)
Lymphocytes (%) 7.3 (4.7) 7.1 (5.8) 7.7 (4.3) 9.29 (4.6)
Data are presented as means (standard deviation). Values are percentage of total cells (for squamous cells) or percentage of leukocytes
(for leukocytes).
*p < 0.05 in the run-in period vs. treatment period.
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for 4 weeks were randomly assigned to low dose of flutica-
sone plus salmeterol or to the same medium dose of flutica-
sone for 24 weeks. The evaluation of specimens obtained by
endobronchial biopsies performed at the end of the run-in
period and at the end of the treatment period failed to
demonstrate changes of inflammatory parameters in any
group.24
In our study, there was no change of sputum eosinophil
counts when the ICSs dose was increased or LABA was added
to low dose of ICSs. It is possible that the low dose of
budesonide had already exerted its maximal anti-inflam-
matory effect during the run-in period, so there was no
benefit in increasing the anti-inflammatory treatment. This
is in concordance with previous studies that demonstrated
that ICSs have a flat dose-response curve, providing
maximal benefits on low or moderate doses.25e27
The differential sputum cell counts revealed that both
treatment groups had their neutrophil counts increased
after the treatment period. The role of neutrophils in the
pathophysiology of asthma is uncertain, although it is
believed that they are involved in exacerbations and that
some corticosteroid-resistant populations have higher
levels of neutrophilic inflammation. Some authors con-
cluded that LABAs have some antineutrophilic action,28,29
but our findings do not corroborate that hypothesis.
Sputum cell culture is not routinely used to assess
inflammation in asthma and, to our knowledge, this is the
first study in which it was employed to compare
inflammation under distinct inhalation therapies. Some
authors and ourselves have used the method to assess
production of inflammatory mediators in vitro30e36;
nevertheless, untreated patients were compared to treated
ones, or stable asthmatics to thosewho underwent bronchial
challenge or suffered from an exacerbation. So, it is still un-
known the role of cell culture to compare two treated
groups.
We observed that cells from individuals in the FORMO
group demonstrated enhanced vitality. This may reflect
some pro-inflammatory action of formoterol. This hypoth-
esis is in accordance with the findings of Kankaanranta
et al., who studied blood cell cultures and concluded that
the eosinophils derived from asthmatic patients not taking
corticosteroids survived longer than the ones derived from
normal subjects. They also reported that incubation of
asthmatics’ blood cell cultures with salmeterol inhibited
eosinophil apoptosis (programmed cell death), thereforeprolonging the survival of these important inflammatory
cells and potentially exerting some pro-inflammatory
effect.37
The levels of inflammatory mediators in sputum and cell
culture medium did not rise or decrease in any treatment
group, suggesting that no further anti-inflammatory effect
was obtained with any treatment strategy compared to the
run-in treatment regimen, perhaps because of the flat
dose-response curve of ICSs and a lack of anti-inflammatory
effect of LABAs.
In conclusion, our findings suggest that adding a LABA to
low-dose ICS or doubling the ICS dose does not modify
significantly the inflammatory status of asthmatics with
moderate to severe disease. This may be due to the flat
dose-response curve of ICS or to the fact that these patients
need even higher doses. The sputum cell culture evalua-
tions led to some concern about pro-inflammatory effects
of LABAs, but further studies are necessary to assess action
of commonly used drugs on inflammatory airway cells. We
also showed that the add-on therapy protects from
exacerbations and improves functional parameters.
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